You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 6,852,687

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,852,687

Title:	Method for inhibiting apoptosis
Abstract:	The present invention relates to a method for treating a subject having a condition or disease involving apoptosis, which comprises administering an effective amount of albumin to the subject. The apoptosis inhibiting activity of albumin can be increased by administering a cell growth factor such as epidermal growth factor, transforming growth factor, fibroblast growth factor, hepatocyte growth factor, insulin-like growth factor, platelet-derived growth factor and nerve growth factor and/or vitamin A together with albumin.
Inventor(s):	Tsubota; Kazuo (Funabashi-shi, Chiba-ken, JP), Higuchi; Akihiro (Kashiwa, JP)
Assignee:	Tsubota; Kazuo (Chiba-ken, JP) Sucampo AG (Zug, CH)
Application Number:	10/132,567
Patent Claims:	1. A method for treating a subject having an ocular surface disorder involving apoptosis, which comprises administering albumin topically to an eye of a subject in need thereof in an amount effective to treat said ocular surface disorder. 2. The method of claim 1, wherein albumin is human origin albumin. 3. The method of claim 1, wherein albumin is a gene recombinant albumin. 4. The method of claim 1, which comprises administrating an effective amount of albumin, together with an effective amount of cell growth factor and/or an effective amount of vitamin A to the subject. 5. The method of claim 4, wherein the cell growth factor is selected from the group consisting of epidermal growth factor, transforming growth factor, fibroblast growth factor, hepatocyte growth factor, insulin-like growth factor, platelet-derived growth factor and nerve growth factor. 6. The method of claim 4, wherein albumin is human origin albumin. 7. The method of claim 4, wherein albumin is a gene recombinant albumin. 8. The method of claim 4, wherein albumin and cell growth factor and/or vitamin A are administrated topically to the eyes. 9. A method for inhibiting an ocular surface disorder involving apoptosis, which comprises administering albumin topically to an eye of a subject in need thereof in an amount effective to inhibit said ocular surface disorder. 10. The method of claim 9, wherein albumin is human origin albumin. 11. The method of claim 9, wherein albumin is a gene-recombinant albumin. 12. The method of claim 9, which comprises administrating an effective amount of albumin, together with an effective amount of cell growth factor and/or an effective amount of vitamin A to the subject. 13. The method of claim 12, wherein the cell growth factor is selected from the group consisting of epidermal growth factor, transforming growth factor, fibroblast growth factor, hepatocyte growth factor, insulin-like growth factor, platelet-derived growth factor and nerve growth factor. 14. The method of claim 12, wherein albumin is human origin albumin. 15. The method of claim 12, wherein albumin is a gene recombinant albumin. 16. The method of claim 12, wherein albumin and the cell growth factor and/or vitamin A are administered topically to the eyes.

Details for Patent 6,852,687

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2021-04-26
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2021-04-26
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2021-04-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.